Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 7/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31648713 | 0.88 | LIPE (0.35) | LIPEIDO1FFAR1TRPV4 | |
| SCHEMBL15751070 | 0.88 | LIPE (0.35) | LIPEIDO1FFAR1TRPV4 | |
| SCHEMBL26608466 | 0.83 | LIPE (0.36) | LIPEFFAR1TRPV4 | |
| SCHEMBL24575389 | 0.81 | LIPE (0.33) | LIPEFFAR1TRPV4 | |
| SCHEMBL25262777 | 0.81 | EGFR (0.38) | LIPE | |
| SCHEMBL31119656 | 0.81 | EGFR (0.38) | LIPE | |
| SCHEMBL1192473 | 0.79 | LPL (0.35) | LIPEUSP30 | |
| SCHEMBL30508802 | 0.79 | LPL (0.35) | LIPEUSP30 | |
| SCHEMBL29781537 | 0.78 | UHRF1 (0.35) | USP30FFAR1 | |
| SCHEMBL12456123 | 0.78 | UHRF1 (0.35) | USP30FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | ACTIO BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250313548-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | ACTIO BIOSCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4466258-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| WO-2023139085-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139085-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| CN-109906224-B | Triazolopyridine compounds and uses thereof | 诺华股份有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-10689378-B2 | Triazolopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-23 | — | — | US | disclosed |
| US-10689378-B2 | Triazolopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-23 | — | — | US | disclosed |
| EP-3472161-B1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-20190202828-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-07-04 | — | — | US | disclosed |
| US-20190202828-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-07-04 | — | — | US | disclosed |
| EP-3472161-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017221092-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313548-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | KCNT1, KCNT2, KCNN3 | LIPE 3568/4885USP30 4436/4885IDO1 4424/4885 |
| US-20190202828-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | EZH2, EED, BMI1 | LIPE 4870/4885USP30 1664/4885IDO1 4307/4885 |
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | KCNT1, KCNT2, KCNJ2 | LIPE 4611/4885USP30 4598/4885IDO1 1863/4885 |
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | H1-3, H1-2, H1-4 | LIPE 4793/4885USP30 4193/4885IDO1 816/4885 |
| US-10689378-B2 | Triazolopyridine compounds and uses thereof | EZH2, EED, BMI1 | LIPE 4870/4885USP30 1664/4885IDO1 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.